Advertisement
Screener

60 DEGREES PHARMACEUTICALS, INC. (SXTP) Long-Term Debt, Maturity, Remainder of Fiscal Year

2.9 / 5 stars · 18/31 Roast Me

60 DEGREES PHARMACEUTICALS, INC. Long-Term Debt, Maturity, Remainder of Fiscal Year

60 DEGREES PHARMACEUTICALS, INC. (SXTP) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $403 as of 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Notes › Commitment and Contingencies

us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2026-08-14

  • 2026-06-30: Long-Term Debt, Maturity, Remainder of Fiscal Year $403.00.
  • 2026-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $403.00.
Period endLong-Term Debt, Maturity, Remainder of Fiscal Year
2026-06-30$403.00
10-Q · filed 2026-08-14
2026-03-31$403.00
10-Q · filed 2026-05-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
REVELATION BIOSCIENCES, INC. (REVB)United States$0.004B
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
Cadrenal Therapeutics, Inc. (CVKD)United States$0.004B-0.90
Onconetix, Inc. (ONCO)United States$0.004B
Aptevo Therapeutics Inc. (APVO)United States$0.003B
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
Sunshine Biopharma Inc. (SBFM)$0.003B
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24